Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (£272m) over five years because of the United States' demand for sensitive biological samples.
This rejection came to light following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesman later clarified that the US was requesting biological samples for scientific study and commercial gain while was not willing to share the benefits from any future treatments.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued talks to reach a agreement suitable to all parties so the nation's critical HIV programme can be sustained.
Wider Background
This rejection follows a similar case in Kenya, where a high court suspended a similar deal with the US following concerns were filed about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to statements, Sixteen African countries have so far agreed to similar agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our population should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining structures previously established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This framework is designed to guarantee that when a country provides its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future co-operation might be structured in a manner that honours the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it acknowledged the official position, but urged that negotiations should continue considering much of the country's HIV programmes were funded by foreign aid.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group commented.
This impasse underscores the complex tensions between accepting crucial international aid and safeguarding a country's data in an increasingly data-driven world.